LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Начало・Списък с акции・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Затворен

СекторЗдравеопазване

16.65 2.59

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

16.14

Максимум

16.88

Ключови измерители
By Trading Economics
Приходи	614M 331M
Продажби	288M 731M
P/E Средно за сектора	48.586 49.888
EPS	3.16
Марж на печалбата	45.287
Служители	835
EBITDA	628M 375M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+36.45% upside

Дивиденти
By Dow Jones
Следващи печалби	5.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-531M 1.8B
Предишно отваряне	14.06
Предишно затваряне	16.65

Настроения в новините

By Acuity

50%

155 / 344 Класиране в Healthcare

Sarepta Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.07.2025 г., 15:04 ч. UTC

Значими двигатели на пазара

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

21.07.2025 г., 11:31 ч. UTC

Значими двигатели на пазара

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

6.05.2026 г., 22:50 ч. UTC

Печалби

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

26.01.2026 г., 09:55 ч. UTC

Горещи акции

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

4.11.2025 г., 14:39 ч. UTC

Печалби

Горещи акции

Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ

4.11.2025 г., 12:45 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More -- Barrons.com

11.08.2025 г., 11:48 ч. UTC

Печалби

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

11.08.2025 г., 11:11 ч. UTC

Печалби

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

29.07.2025 г., 21:11 ч. UTC

Печалби

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

29.07.2025 г., 12:14 ч. UTC

Печалби

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

29.07.2025 г., 11:46 ч. UTC

Печалби

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

21.07.2025 г., 12:53 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

21.07.2025 г., 11:17 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

21.07.2025 г., 10:25 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

21.07.2025 г., 09:50 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

21.07.2025 г., 09:12 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

17.07.2025 г., 16:44 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

17.07.2025 г., 13:48 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

17.07.2025 г., 10:57 ч. UTC

Печалби

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

17.07.2025 г., 09:08 ч. UTC

Горещи акции

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

17.06.2025 г., 09:10 ч. UTC

Горещи акции

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

17.06.2025 г., 08:59 ч. UTC

Горещи акции

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

16.06.2025 г., 08:55 ч. UTC

Горещи акции

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Sarepta Therapeutics Inc Прогноза

Ценова цел

By TipRanks

36.45% нагоре

12-месечна прогноза

Среден 22.16 USD 36.45%

Висок 38 USD

Нисък 5 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Sarepta Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Sarepta Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

155 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.